Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Schjesvold FH, et al. Among authors: symeonidis a. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece. Terpos E, et al. Among authors: symeonidis a. Eur J Haematol. 2010 Aug;85(2):114-9. doi: 10.1111/j.1600-0609.2010.01466.x. Epub 2010 May 6. Eur J Haematol. 2010. PMID: 20477863
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: symeonidis a. Eur J Haematol. 2012 Jul;89(1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x. Eur J Haematol. 2012. PMID: 22469521
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E. Katodritou E, et al. Among authors: symeonidis a. Ann Hematol. 2014 Jan;93(1):129-39. doi: 10.1007/s00277-013-1841-y. Epub 2013 Jul 28. Ann Hematol. 2014. PMID: 23892921
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E, Dimopoulos MA; Greek Myeloma Study Group. Zagouri F, et al. Among authors: symeonidis as. Eur J Haematol. 2014 Apr;92(4):308-12. doi: 10.1111/ejh.12255. Epub 2014 Jan 26. Eur J Haematol. 2014. PMID: 24460646
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Katodritou E, et al. Among authors: symeonidis as. Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12. Am J Hematol. 2014. PMID: 24757085 Free article.
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Katodritou E, et al. Among authors: symeonidis as. Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30. Ann Hematol. 2015. PMID: 26420061 Clinical Trial.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Dimopoulos MA, et al. Among authors: symeonidis a. Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10. Lancet Oncol. 2017. PMID: 27956157 Clinical Trial.
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Zagouri F, et al. Among authors: symeonidis a. Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26. Eur J Haematol. 2017. PMID: 28675766
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: symeonidis a. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Ann Hematol. 2018. PMID: 29756171 Free PMC article.
270 results